ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQUIS GROWTH MARKET
|
|
APPLICANT NAME:
|
Blackpoint Biotech plc
|
APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:
|
48-49 Chancery Lane, C/O Keystone Law, London, England, WC2A 1JF
+44 208 050 6458
|
DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):
|
- Michael William Balfour, Non-Executive Chairman
- David Manuel Martinez, Chief Executive Officer
- Alexander James Robert Stormont Wakeford, Chief Financial Officer
- Dr Michael Barry Mayne, Chief Product Officer
|
APPLICANT SECTOR:
|
Healthcare
|
DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:
|
Blackpoint Biotech PLC is a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing.
|
NAME OF AQSE CORPORATE ADVISER:
|
First Sentinel Corporate Finance Limited
|
NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:
|
12,187,179 Ordinary Shares of £0.005 each
|
SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):
|
15.12%
|
SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:
|
Shareholder
|
Shares
Pre-admission
|
%
Pre-admission
|
Shares
Post-admission
|
%
Post-admission
|
David Martinez
|
4,078,102
|
33.46%
|
4,078,102
|
33.46%
|
Alexander Wakeford
|
1,581,696
|
12.98%
|
1,581,696
|
12.98%
|
Michael Mayne
|
2,105,000
|
17.27%
|
2,105,000
|
17.27%
|
Creedy Carver Chickens Limited
|
2,271,410
|
18.64%
|
2,271,410
|
18.64%
|
|
TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:
|
N/A
|
THE EXPECTED ADMISSION DATE:
|
TBD
The company has applied to Euroclear to have the shares enabled in CREST and the process has not yet been concluded.
|
WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:
|
www.blackpointbiotech.com
|
In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:
|
UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:
|
06 July 2023
|